ALBERT B. SABIN VACCINE INSTITUTE, INC. (THE): $224M Department of Health and Human Services Contract
Summary
The Department of Health and Human Services awarded a $224M definitive contract to the Albert B. Sabin Vaccine Institute, a private entity, for Marburg virus advanced R&D and preparedness. As the recipient is not publicly traded, no direct stock impact is identified, but the contract signals increased government focus on pandemic preparedness, which may benefit the broader healthcare sector.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.The $224M contract to a private entity does not directly impact any publicly traded company's revenue.
- 2.The contract underscores government prioritization of Marburg virus preparedness, which may indirectly benefit vaccine-related ETFs or sector funds.
- 3.Investors should monitor future subcontract awards or licensing deals that could involve public companies.
Market Implications
The contract is a positive signal for the healthcare sector's pandemic preparedness subsector, but with no public company directly benefiting, the market impact is muted. Investors in vaccine-related stocks should watch for any subcontracting announcements or technology transfer agreements that could involve public firms like $DVAX or $NVAX, though no such links are confirmed.
Full Analysis
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
AVITA MEDICAL AMERICAS, LLC: $25.5M Department of Health and Human Services Contract
GENERAL DYNAMICS INFORMATION TECHNOLOGY, INC.: $14.4M Department of Health and Human Services Contract
ANGEL DESIGN BUILD CONSTRUCTION LLC: $12.4M Department of Veterans Affairs Contract
BELLESE TECHNOLOGIES, LLC: $25.8M Department of Health and Human Services Contract
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Promoting Efficiency, Accountability, and Performance in Federal Contracting
This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.
Accelerating Medical Treatments for Serious Mental Illness
This executive order directs the FDA to prioritize review and facilitate 'Right to Try' access for psychedelic drugs, including ibogaine compounds, that have received Breakthrough Therapy designation for serious mental illnesses. It also allocates $50 million from HHS to support state programs advancing these treatments and mandates collaboration between HHS, FDA, VA, and the private sector to increase clinical trial participation and data sharing for these drugs. The Attorney General is further directed to expedite rescheduling reviews for approved Schedule I psychedelic substances.
Contract Details
Recipient
ALBERT B. SABIN VACCINE INSTITUTE, INC. (THE)
Award Amount
$223,798,184
Awarding Agency
Department of Health and Human Services
Sub-Agency
Office of Assistant Secretary for Preparedness and Response
Contract Type
DEFINITIVE CONTRACT
Related Bills